January 10th 2025
The adcomm meeting is expected to happen in the first half of 2025, and means the FDA expects to miss the target PDUFA date.
May 3rd 2024
The sNDA for the brexpiprazole plus sertraline therapy is based on positive phase 2 and 3 clinical trials showing improvement in PTSD-specific scale scores.
Optimizing PTSD Treatment: The Role of Brexpiprazole and Sertraline in Future Guidelines
Brexpiprazole and sertraline showed promise for PTSD treatment in a recent study. Lead author, Lori Davis, MD, discusses clinical findings, treatment guidelines, and future research directions.
PTSD Treatment Advancements: Brexpiprazole-Sertraline Offers New Hope in Phase 3 Trial
Data showed that brexpiprazole plus sertraline significantly improved PTSD symptoms vs sertraline alone. Lead author, Lori Davis, MD, discusses more.